Kardiotoxicita a kardiovaskulární nežádoucí účinky
| Title in English | Cardiotoxicity and cardiovascular side effects |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Chapter of a book |
| MU Faculty or unit | |
| Citation | |
| Description | Cardiotoxicity is one of the serious side effects of oncology treatment, it is most often associated with anthracycline (doxorubicin, epirubicin, daunomycin), less frequently anthracenoids (mitoxantrone). Alkylating agents are cardiotoxic primarily at higher doses (cyclophosphamide, ifosfamide). Rarely cardiotoxicity was described in 5-fluorouracil, mitomycin C, cisplatin, vincristine, bleomycin and paclitaxel treatment. Cardiotoxicity is now also reported in targeted anti-cancer treatments, especially anti-HER2 drugs (trastuzumab, pertuzumab, trastuzumab emtansin, lapatinib). |